La inteligencia emocional del alumnado de Educación Primaria en un aula con metodología tradicional frente a un aula con metodología innovadora : estudio en una muestra de Sevilla

Con la presente investigación se pretende establecer una comparación entre los centros con una metodología tradicional frente a los colegios con una metodología más innovadora, a fin de determinar cómo influye esta en el desarrollo de la inteligencia emocional de los alumnos. La investigación se lleva a cabo en dos centros pertenecientes a la provincia de Sevilla, donde se realiza un cuestionario en cada uno de ellos a un grupo de alumnos para conocer cuál es el desarrollo de su inteligencia emocional y cuáles son las actitudes desarrolladas hacia el estudio. Tras el análisis de los resultados, se concluye que en nuestra muestra, en los centros donde se lleva a cabo una metodología educativa innovadora mediante las comunidades de aprendizaje se halla en el alumnado una mayor inteligencia emocional obteniéndose puntuaciones más altas en casi todas sus dimensiones.The study conducts a comparison between schools that implement traditional methodologies and schools that implement innovative methodologies to determine how each method influences the students´development of emotional intelligence. This investigation took a place in two schools located in the province of Seville. In each school, the students participating received questionnaires. The objective of the questionnaire was to understand how the students felt prior to each lesson and how their emotional intelligence developed throughout. After analyzing the results from our sample, we can conclude that the innovative methodology carried out by schools have more direct relationship with emotional intelligence than those who do not practice it. Students using the innovative methodology obtain higher marks in the majority of their studies

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols